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COVID-19 in Italian patients with rheumatic 
autoimmune systemic diseases
We followed with great interest the numerous reports published 
by the Annals1–9 as regards the impact of the COVID-19 
pandemic on different rheumatic autoimmune systemic diseases 
(ASD), including the survey study by Costa et al9 that under-
lined the usefulness of telerheumatology in the management 
of patients with psoriatic arthritis in COVID-19 era. On the 
same topic, the world literature encompasses a large number 
of anecdotal observations, cohort studies and telephone 
surveys.1–15 Overall, the observed prevalence of symptomatic 
COVID-19, usually as mild- moderate disease, in patients with 
chronic arthritis was comparable to that found in the general 
population, while worse outcomes represented almost rare 
events.1–15 Conversely, increased percentages of symptomatic 
COVID-19 were observed in patient cohorts with connective 
tissue diseases, especially systemic lupus or systemic vascu-
litis.6 7 Of note, in ASD complicated by COVID-19, the base-
line use of immune modifiers, namely, conventional synthetic 
(csDMARD), biological (bDMARD) and targeted synthetic 
disease- modifying antirheumatic drugs (tsDMARD), was not 
associated with worse COVID-19 disease outcomes.3–5 9 10 
Almost invariably these monocentre studies focused on ASD 
patients’ populations from limited geographical areas.1–15 Given 
the heterogeneous distribution of pandemic infection within 
the same country, we investigated the impact of COVID-19 in 
ASD patients’ populations from three distinct regions of Italy 
(northern, Emilia Romagna; central, Tuscany; and southern, 
Calabria), characterised by different spread of the COVID-19 
pandemic, prevalent in northern Italy with a marked gradient 
north- south.16 Our 6- week multicentre telephone survey 
of 1641 unselected patients with ASD confirmed the quite 
benign clinical course of COVID-19 in ASD, along with the 
safety of baseline use of either bDMARD or tsDMARD1–15; 
however, the survey revealed a significantly higher prevalence 
of (1) either definite COVID-19 (always confirmed by positive 
oral/nasopharyngeal swabs at PCR testing) or highly suspected 
COVID-19 (presence of fever and/or known contact with 
infected subject, and at least 4 out of 12 typical signs/symp-
toms of COVID-19) in patients with ASD compared with the 
Italian, or regional, general population; (2) definite COVID-19 
plus highly suspected COVID-19 in connective tissue diseases 
(CTD)/vasculitis (703 patients) compared with the subgroup 
of chronic arthritis (938 patients with rheumatoid arthritis, 
psoriatic arthritis or ankylosing spondylitis); and (3) definite 
COVID-19 plus highly suspected COVID-19 in ASD patients 
without ongoing csDMARD.16
Although a number of issues still remain to be better investi-
gated, we can draw some provisional considerations based on 
the whole of currently available data:
 ► The actual prevalence of COVID-19 in patients with ASD 
might be underestimated, possibly due to concurrent 
factors, mainly the high rate of mild COVID-19 variants, 
the frequent clinical overlapping between ASD and COVID-
19, and the limited availability of virological test that may be 
critical for differential diagnosis in many individuals.
 ► Despite increased susceptibility to infections that char-
acterise patients with ASD, the impact of the COVID-19 
pandemic revealed less severe than initially feared, particu-
larly in countries with well- organised healthcare systems. It 
is very likely that the patients’ awareness of the risks inherent 
to their chronic illness along with the disease- related 
physical limitations have conditioned the patients’ lifestyle 
and reduced the probability of contracting COVID-19.
 ► In this context, the telemedicine applications may play 
an important role in the care of ‘frail patients’ in general, 
and patients with ASD in particular, during the COVID-19 
pandemic peak or its possible re- exacerbation.
 ► The treatment with immune modifiers, that is, csDMARD, 
bDMARD and/or tsDMARD, commonly used in patients with 
chronic arthritis, has proven to be quite safe, even if avail-
able data warrant closer surveillance of patients with ASD on 
chronic immune- modulating treatments. On the other hand, 
these drugs might play some protective role against the most 
harmful manifestations of COVID-19 such as pneumonia 
and acute respiratory distress syndrome secondary to the 
cytokine storm. The results of ongoing trials to assess the 
efficacy and the correct timing in the introduction of anti-
rheumatic drugs in patients with COVID-19 could clarify 
these important issues. On the basis of indirect observations 
suggested by real- life experience, ongoing chronic treat-
ments with one or more immune modifiers at the time of 
COVID-19 infection (hydroxychloroquine, methotrexate, 
tocilizumab or baricitinib) might damper or prevent the 
more severe COVID-19 manifestations. The observed ther-
apeutic failure of these drugs, introduced after the clinical 
onset of COVID-19 manifestations, could be related to 
their prolonged latency of action, while the employed high 
dosages may be responsible of frequent serious side effects.
 ► Noteworthy, patients with CTD/vasculitis compared with 
different chronic arthritis (rheumatoid arthritis, psoriatic 
arthritis and ankylosing spondylitis) showed a higher prev-
alence of COVID-19, as possible consequence of deeper 
immune- system dysfunction present in these disorders. 
Therefore, the heterogeneous subgroup of CTD/vasculitis 
should deserve well- tailored management strategies in the 
COVID-19 era.
 ► The epidemiology of this novel coronavirus is little known 
as regards the course of the ongoing pandemic, possible 
re- exacerbations and/or new waves.17 In addition, possible 
virus- driven immune- mediated organ damages as delayed 
COVID-19 manifestations cannot be ruled out at all, particu-
larly in individuals with basically altered immune reactivity. 
Although the majority of patients with ASD developed mild- 
moderate COVID-19 disease, the long- term consequences 
of viral infection remain largely unpredictable.
 ► Direct and/or immune- mediated organ damages of 
COVID-19 infection represent a major challenge; both 
severe interstitial lung involvement that may evolve to 
fibrosis and diffuse microangiopathy seem to reproduce 
typical pathological features observable in the course of 
various ASD, particularly the systemic sclerosis. In- depth 
pathogenetic studies are required to better clarify the 
possible virus interaction with host immune system and the 
mechanism(s) involved in the tissue injuries.
 ► In the clinical practice, shared clinical guidelines are highly 
advisable in order to identify ASD patients’ subgroups at 
high risk of infection, such as CTD/vasculitis patients, which 
may deserve differentiated therapeutic protocols, as well as 
predictive parameters of worse outcomes.
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